Call for Abstract
Scientific Program
World Congress on Hepatitis, will be organized around the theme “Raising global awareness on hepatitis and fighting the stigma surrounding the disease”
Hepatitis 2015 is comprised of 10 tracks and 54 sessions designed to offer comprehensive sessions that address current issues in Hepatitis 2015.
Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
- Track 1-1Viral hepatitis and autoimmune hepatitis
- Track 1-2Interferon-free treatment of hepatitis C
- Track 1-3Advance management of viral hepatitis
- Track 1-4Hepatitis B virus epidemiology, course, and diagnosis
- Track 1-5Alcoholic hepatitis: clinical manifestations and diagnosis
- Track 1-6New molecules for the hepatitis treatment
- Track 1-7Extrahepatic manifestations of hepatitis C virus infection
- Track 2-1Abnormal liver tests and drug induced liver diseases
- Track 2-2Screening for liver diseases
- Track 2-3Liver biochemistry tests in the diagnosis and management of liver disease
- Track 2-4The impact of diagnosis of hepatitis C virus on quality of life
- Track 2-5Sampling variability of liver fibrosis in chronic hepatitis C
- Track 3-1Alcoholic liver disease and nonalcoholic fatty liver disease
- Track 3-2Microbiota and vascular diseases of the liver
- Track 3-3Cholestatic and metabolic liver diseases
- Track 3-4Primary biliary cirrhosis
- Track 3-5Hepatic encephalopathy
- Track 3-6Haemochromatosis and liver fibrogenesis
- Track 4-1Cellular plasticity in liver cancer
- Track 4-2Reprogramming and pathogenesis of hepatocellular carcinoma
- Track 4-3The role of cancer stem cells in hepatocellular carcinoma
- Track 4-4Senescence, immune response and hepatocarcinogenesis
- Track 4-5Clinical controversies in liver cancer
- Track 4-6Molecular classification and novel targets in hepatocellular carcinoma
- Track 4-7Effect of alcohol, smoking and tobacco on hepatocellular carcinoma
- Track 4-8Prevention of hepatocellular carcinoma
- Track 4-9Emerging concept of understanding liver cancer immunity and cancer stem cells
- Track 5-1Hepatobiliary diseases in relation to pathophysiology, treatment and prevention
- Track 5-2Clinical implications of inflammation and immunity in liver disease
- Track 5-3Liver fibrosis etiology
- Track 6-1Acute liver failure and liver transplantation
- Track 6-2Artificial liver support and liver transplantation for chlolangiocarcinoma
- Track 6-3Minimally invasive hepato-pancreato-biliary surgery
- Track 6-4Surgical and infectious complications of liver transplant
- Track 6-5Pediatric indications for liver transplantation
- Track 6-6Long term complications following liver transplant
- Track 6-7Controversies in liver transplantation
- Track 7-1Hepatitis A virus infection and the waste handling industry
- Track 7-2Industrial chemicals associated with toxic hepatitis
- Track 7-3Chemicals associated with abnormal liver function test
- Track 8-1Sofosbuvir plus simeprevir for genotype 1 chronic hepatitis C infection
- Track 8-2Sofosbuvir for genotype 2 and 3 chronic hepatitis C infection
- Track 8-3Ribavirin for chronic hepatitis E infection in transplant recipients
- Track 9-1Ultrasound-based transient elastography in chronic liver disease
- Track 9-2Potential for interferon-free regimens in chronic HCV genotype 1 infection
- Track 9-3Nonselective beta blockers in patients with cirrhosis and spontaneous bacterial peritonitis
- Track 9-4Protease inhibitors for hepatitis C virus recurrence after liver transplantation
- Track 9-5Diagnostic paracentesis for cirrhosis and ascites
- Track 10-1Recent advances in hepatitis C virus therapy
- Track 10-2Enhancing management treatment of HCV in the Direct Acting Antiviral Era
- Track 10-3Changing treatment landscapes in hepatitis B and C
- Track 10-4Advances in managing patients with hepatocellular carcinoma and viral hepatitis
- Track 10-5Intrahepatic cholestasis of pregnancy and hepatitis C virus
- Track 10-6Polycystic Liver Disease